Friday , May 20 2022

NIH-funded birth control natal process



[ad_1]

The National Institute of Health (NIH) finalizes trial for a man with a transdermal birth defect against pregnancy prevention.

NES / T rooms called progesterone compound acetate (Nestorone) plus testosterone. The Population Council and NIH Eunice Kennedy Shriver developed the National Child Health and Human Development Institute (NICHD).

"Many women can not use hormonal contraceptives and menstruation methods restrict vasectomy and condoms. Safe, highly effective and reversible method of masculine contraceptive should be met by an important public health need," said researcher Diana Blithe, NICHD's chief of Contraceptive Development Program, he said.

NES / T is applied to the gel on the shoulders and shoulders. Progestin produces natural testosterone, reducing sperm to lesser degree. Alternative testosterone usually maintains the dependency of the sexual unit and other appropriate hormone levels, which explains the NIH.

Daily applied gel amount approximately 5 mL volume (2.5 mL shoulder and each arm each day). This daily gel volume volume of 62 mg testosterone 6 mg testosterone delivered daily body plus 8 mg azesterazide acid that delivered 0.8 mg of acetylene acetyl on the body per day.

The test protocol has a duration of 4 to 8 weeks duration, suppression phase of about 20 weeks, 52 weeks of maintenance / efficacy phase (pregnancy prevention) and 24 weeks (estimated) recovery phase. In pregnancy prevention, the couple stops the application of the male room as the only method of contraception.

This is a prospective, phase 2b, open label, single-arm, multicenter analysis. Recruitment is continuous and 420 pairs will be gathered in nine clinic sites (30 to 60 pairs per site).

The Population Council collaborates with NIH in the NICHD Contraceptive Clinical Trials Network (CCTN) in two areas: the Los Angeles Biomedical Institute and the Los Angeles Medical Center at the University of California, Christina Wang, MD, and the University's principal researcher Seattle, Seattle, lead researcher Stephanie Page, MD, PhD.

Seven collaborative study centers (and researchers) are:

  • Kansas University, Overland Park (Ajay Nangia, MBBS)

  • University of Edinburgh, Scotland, United Kingdom (Richard Anderson, MD, PhD)

  • Manchester University, United Kingdom (Cheryl Fitzgerald, MD)

  • Karolinska Institute, Stockholm, Sweden (Kristina Gemzell Danielsson, MD, PhD)

  • Kenyatta National Hospital, Nairobi, Kenya (John Kinuthia, MBChB)

  • The Chilean Institute of Recurrent Medicine, Santiago (Gabriela Noe)

  • Bologna University, Italy (Cristina Meriggiola, MD, PhD)

The main prediction of the study is the end date ending on July 2021.

For more news, please contact us Facebook and Twitter

[ad_2]
Source link